Because of this, a minor set of five additional markers (CD99, GD2, CD271, EpCAM, and numyogenin) was selected from all tumor-associated proteins investigated, for the differential diagnosis between the four major subgroups of extracranial SRCT vs. other pediatric tumors. Here, CD99 is linked to neoplasm.